HCGRP-_8-37__SDS_MedChemExpress
人绒毛膜促性腺激素单克隆抗体的研制及其β亚基羧基末端37肽（βhCG-CTP..
人绒毛膜促性腺激素单克隆抗体的研制及其β亚基羧基末端37肽(βhCG-CTP)真核表达的研究摘要人绒毛膜促性腺激素(human chorionic gonadotrophin，hCG)是人类受孕后胎盘合体滋养层细胞分泌的一种糖蛋白激素，是最早出现的妊娠特异性物质，hCG的合成与分泌与妊娠密切相关。
在妊娠早期hCG的浓度迅速升高，检测尿中的hCG即可证实妊娠，因此，抗hCG单克隆抗体的研制对于早早孕检测具有重要意义。
但用完整的抗hCG分子抗体检测hCG时与LH间有免疫交叉反应。
而hCG的β亚基羧基端109~145残基组成的37肽(human chorionic gonadotrophin-β carboxyl terminal peptides，βhCG-CTP)是hCG分子所特有的片段，并存在hCG的特异表位(抗原决定簇)，其抗体具有更好的hCG抗原特异性，不会与促黄体生成激素(luteinizint hormone,LH)发生交叉反应。
采用抗βhCG羧基末端37肽单克隆抗体可以进一步提高检测的敏感性和特异性并为避孕疫苗的研制奠定基础。
因此，本研究在成功地制备了hCG单克隆抗体之后，进一步真核克隆表达了βhCG-CTP，为下一步基因免疫法制备单克隆抗体作了一定的准备，也为hCG基因避孕疫苗的研制奠定了基础。
第一部分人绒毛膜促性腺激素单克隆抗体的研制目的获得针对人绒毛膜促性腺激素单克隆抗体。
方法 hCG蛋白免疫Balb/c小鼠，取其脾细胞与同系小鼠骨髓瘤细胞NS-1按8:1比例融合，用间接ELISA法筛选阳性克隆，再用有限稀释法进行扩大及克隆化培养；经对杂交瘤细胞株进行核型分析和克隆化培养，得到能稳定分泌单克隆抗体的杂交瘤细胞株；以此杂交瘤细胞接种小鼠腹腔，制备腹水抗体；收集抗体，采用间接ELISA法鉴定抗体亚型、测定抗体效价和抗体特异性及交叉反应性比较。
结果 1. 共免疫8只小鼠，血清抗体效价均达10-6以上，说明免疫效果较好，可进行细胞融合；2. 得到6株能稳定分泌单克隆抗体的杂交瘤细胞株，间接ELISA法测定其OD值均在1.0以上，说明分泌抗体的能力较强，在克隆化培养过程中，其OD值均呈稳定升高趋势，说明细胞株分泌抗体的稳定性良好；3. 制备的腹水抗体经鉴定均为IgG1、κ型，效价均达10-5以上；4. 以hCG、LH、α-LH、β-LH分别包被酶标板检测经两次克隆化的A1a1、A2a1、A3a1、A4a1、A5a1、A6a1 6株细胞株培养上清与它们的交叉反应性，结果显示：6株杂交瘤细胞株培养上清与hCG反应的OD值都在1.0以上，说明6株杂交瘤细胞株分泌抗hCG单克隆抗体的能力较强。
迈瑞常规生化复合校准品参考靶值单
2.52
2.48
氧化酶法
mmol/L 4.03
4.20
4.10
4.10
连续监测法 改良苦味酸法 肌氨酸氧化酶法
U/L
343
339
342
342
µmol/L 295
298
290
290
µmol/L 342
342
342
342
葡萄糖 GLU
γ-谷氨酰转移酶 GGT
α-羟丁酸脱氢酶 α-HBDH
乳酸脱氢酶 LDH
U/L
265
267
269
269
U/L
86.6 91.4 88.7 89.5
α-淀粉酶 α-AMY
连续监测法
U/L
198
天门冬氨酸氨基转 移酶 AST
IFCC 法
U/L
95.8
直接胆红素
重氮法（对氨基苯磺酸） µmol/L 42.5
DB
钒酸盐氧化法
µmol/L 40.0
199
203
203
98.7 101.8 100.0
42.5 42.5 42.5 40.0 42.5 42.5
总胆红素 TB
钙 Ca 总胆固醇 TC 肌酸激酶 CK
肌酐 Crea
重氮法（对氨基苯磺酸） µmol/L 94.4
94.4
83.7
83.7
钒酸盐氧化法
µmol/L 91.0
91.0
83.7
83.7
偶氮胂 III 法
mmol/L 2.45
2.45
项目
常规生化复合校准品参考靶值单
常规生化复合校准品
批号：MSK0901-R 效期：2010-11
XMD8-87_DataSheet_MedChemExpress
Inhibitors, Agonists, Screening Libraries Data SheetBIOLOGICAL ACTIVITY:XMD8–87 is a potent TNK2 inhibitor with IC 50 values of 38 and 113 nM for the D163E and R806Q mutations, respectively.IC50 & Target: IC50: 38 nM (TNK2, D163E mutation), 113 nM (TNK2, R806Q mutation)[1]In Vitro: XMD8–87 potently inhibits the growth of the TNK2 mutant expressing cell lines while having little or no effect on the control cells out to the highest tested concentrations (1,000 nM). XMD8–87 has IC 50s of 38 nM and 113 nM for the D163E and R806Q mutations. The effects of XMD8–87 on TNK2 cell lines are largely due to on–target effects on TNK2. Auto–phosphorylation of overexpressed TNK2 mutants could be blocked with TNK2 inhibitor XMD8–87[1].PROTOCOL (Extracted from published papers and Only for reference)Kinase Assay:[1]Kinase targets are tested with biochemical enzymatic kinase assays using the SelectScreen Kinase Profiling Service to determine IC 50 values. The compounds (XMD8–87) are assayed at 10 concentrations (3–fold serial dilutions starting from 1 μM) at an ATP concentration equal to the ATP Km [1].Cell Assay:[1]Cells are treated with the following inhibitors for 72 hours: dasatinib, AIM–100, XMD8–87 and XMD16–5. Cell viability is measured using a methanethiosulfonate (MTS)–based assay and absorbance (490 nm) is read at 1 and 3 hours after adding reagent [1].References:[1]. Maxson JE, et al. Identification and Characterization of Tyrosine Kinase Nonreceptor 2 Mutations in Leukemia through Integration of Kinase Inhibitor Screening and Genomic Analysis.Product Name:XMD8–87Cat. No.:HY-15811CAS No.:1234480-46-6Molecular Formula:C 24H 27N 7O 2Molecular Weight:445.52Target:Tyrosinase Pathway:Metabolic Enzyme/Protease Solubility:DMSO: ≥ 26 mg/mLCaution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@ Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。
人绒毛膜促性腺激素测定SOP_HCG临床意义_检验科生化项目SOP
人绒毛膜促性腺激素测定SOP_HCG临床意义_检验科生化项目SOP人绒毛膜促性腺激素（HCG）是一种由绒毛细胞和合体细胞分泌的糖蛋白类激素，在妊娠早期能催化黄体生成与分泌的孕酮，维持胎盘的发育与功能。
因此，人绒毛膜促性腺激素测定对于妊娠的诊断和监测非常重要。
本文将详细介绍人绒毛膜促性腺激素测定的操作规程（SOP）以及其临床意义。
一、人绒毛膜促性腺激素测定SOP（一）实验前准备1.验证并保持检测设备的正确运行2.准备检测所需试剂和标准品3.校准仪器至正常运行状态（二）样本处理1.收集妊娠早期静脉血样本2.氯化铋沉淀法分离澄清血清3.将澄清的血清样本转移到离心管中，避免氧化处理4.将样本储存于-20℃的冰箱中，避免多次冻融（三）实验操作1.取出样品并在流动室中解冻2.准备所需的工作液和一系列稀释标准品3.在试管中加入合适比例的标准品和待测样本，加入检测试剂4.在试管中加入酶标板置换盘，封闭孔洞，置于恒温水槽中孵育5.用洗涤缓冲液洗涤酶标板孔洞6.在每个孔洞中加入底物溶液，孵育15分钟7.加入底物溶液的反应停止液，读取吸光度8.用标准曲线计算样本中HCG的浓度9.记录测定结果并及时提交给相关医师（四）实验后处理1.清洗仪器和耗材2.周期性校准仪器3.根据SOP中的操作规程进行结果分析和报告二、临床意义（一）妊娠诊断HCG是妊娠初期最早出现的标志物之一，其测定可以明确是否存在怀孕。
在正常情况下，怀孕后的6-8天，HCG可以在血液中检测到。
因此，HCG的测定可以用于妊娠的早期诊断。
（二）妊娠监测HCG的浓度在妊娠早期不断上升，可以通过连续测量来监测胎儿的发育情况。
如果HCG的浓度没有按预期增加，可能表明胎儿发育不良、妊娠停止或其他异常情况。
因此，HCG的测定可以用于判断妊娠的进展和胎儿的状态。
（三）异常妊娠的检测HCG的浓度异常增加或减少可能是异常妊娠的指示。
例如，妊娠期超过6周，但HCG浓度低于预期水平，可能提示存在宫外孕。
游离β—人绒毛膜促性腺激素(Freeβ—hCG)测定试剂盒产品技术要求深圳市宇诺生物
游离β-人绒毛膜促性腺激素（Freeβ-hCG）测定试剂盒（化学发光免疫分析法）1.性能指标1.1外观试剂盒各组分应齐全、完整，液体无渗漏；中文包装标签应清晰，无破损。
酶标记物应为清澈均匀的液体，无沉淀，无絮状物；磁微粒应无板结，液体无絮状物，无异物。
校准品、质控品应为澄清液体，应无肉眼可见杂质。
1.2装量各组分实际装量应不少于标示值。
1.3准确度用国家标准品作为样本进行检测，其测量结果的相对偏差应在±10.0％范围内。
1.4空白限应不大于0.05ng/mL。
1.5线性在0.1ng/mL～190ng/mL 浓度范围内，剂量-反应曲线线性相关系数r 应≥0.9900。
1.6精密度1.6.1批内精密度测试高低质控品各10 次，其变异系数（CV）应不大于8.0%。
1.6.2批间精密度使用3 个批号试剂检测同一批高低值质控品各10 次，测定结果的变异系数（CV）应不大于10.0%。
1.7特异性测定浓度为200μIU/mL 的促甲状腺素（TSH）、浓度为200mIU/mL 的促卵泡生成素（FSH）、浓度为200mIU/mL 的促黄体生成素（LH）样本，其测定结果均应不高于1.25ng/mL，测定浓度为1000mIU/ mL 的人绒毛膜促性腺激素（HCG）样本，其测定结果应不高于2.50ng/ mL。
1.8质控品测定值配备定值质控品的试剂盒，其测定结果应在试剂盒规定的范围内。
1.9校准品准确性校准品测量结果相对偏差应在±10%以内。
1.10质控品准确性质控品测量结果应均在靶值范围内。
1.11校准品均一性校准品的均一性CV 应≤10%。
1.12质控品均一性质控品的均一性CV 应≤10%。
hcc中稳定高表达的免疫组化蛋白
hcc中稳定高表达的免疫组化蛋白
在肝细胞癌（HCC）中，有一些免疫组化蛋白的高表达可以
被视为稳定的。
以下是一些常见的免疫组化蛋白在HCC中的
高表达情况：
1. 高表达的标志性蛋白：Cytokeratin 8/18（CK8/18）和Hepatocyte Paraffin 1（Hep Par 1）被广泛用于HCC的诊断和
鉴别诊断。
这些蛋白在HCC中通常高表达，而在正常肝组织
和其他类型的癌症中低表达。
2. 上皮标记蛋白：Epithelial Cell Adhesion Molecule（EpCAM）和Carcinoembryonic Antigen（CEA）在HCC中也被发现高表达。
这些蛋白在肿瘤细胞上过度表达，有助于HCC的诊断和
治疗。
3. 细胞增殖标志物：Ki-67是一个细胞增殖标志物，它在活跃
的细胞周期中高表达。
在HCC中，Ki-67通常高表达，可以
用来评估肿瘤的增殖活性。
4. 血管生成标志蛋白：Vascular Endothelial Growth Factor （VEGF）和CD34是血管生成标志蛋白，在HCC中高表达。
这些蛋白参与肿瘤血管生成和生长，对HCC的治疗和预后预
测具有重要意义。
值得注意的是，具体的免疫组化蛋白表达情况可能因个体差异和HCC亚型的不同而有所变化。
因此，在特定个案中，其他
免疫组化蛋白的高表达也可能被用于HCC的诊断和分类。
人基质质控血清
注释：
®：注册商标
(1). 只适用于德国。
根据德国内科医生联邦议院的方针制订范围(中文说明已略，如需请另行参见英文说明)。
(2). 德国内科医生联邦议院官方认可的参考实验室测定的浓度值。
(3). DGKC：德国临床化学协会
(4). IFCC：国际临床化学联盟
(5). SCE：斯堪的纳维亚酶委员会
使用说明
朗道的人基质质控血清为冻干品，用于临床准确性或者重复性质量控制。
朗道供应2种水平的质控血清。
赋值
每一批质控血清都要送到参考实验室，根据国际参考标准进行赋值。
若没有国际参考标准，就使用参考方法。
朗道也将质控血清送到全世界3000多家实验室，然后将结果用相同的统计分析赋值。
质控范围值是平均值±2S.D.。
该结果非常准确可靠，实验室尽可放心使用。
准备
1. 小心打开瓶盖，避免内容物的任何损失。
2. 在20-25℃的室温下，准确量取5ml蒸馏水复溶1瓶质控血清。
3. 盖上橡皮塞，拧紧瓶盖，使用前避光放置30分钟。
4. 轻轻旋转，确保内容物完全溶解。
5. 将小瓶倒置，确保所有的冻干物完全溶解。
6. 勿摇晃小瓶。
复溶后的血清既可以用于手工测试，也可以用于全自动生化分析仪。
该血清只能按照上述步骤复溶。
稳定性
该血清自生产之日起，在4℃下保存可以稳定4年。
效期标在试剂盒的侧面。
该血清一旦复溶，在25℃下可以稳定24小时，在4℃下可以稳定7天，在-20℃至少可以稳定1个月（见受限情况）。
妊娠期高血压疾病患者血浆纤维凝胶蛋白-3、正五聚蛋白3表达及临床意义
l
i
nkedimmuno
s
o
r
ben
ta
s
s
ay(
ELI
SA)wa
sus
edt
ode
t
e
c
tt
hep
l
a
smaf
i
c
o
l
i
n
yme
３andPTX３l
e
ve
l
so
ft
hewomeni
nt
he
s
eg
r
oups．Pe
a
r
s
on me
t
hod wa
sus
edt
oana
l
z
et
hec
o
r
r
e
l
a
t
i
onbe
曲线(
ROC)分析血浆 f
i
c
o
l
i
n
３、
PTX３ 对 HDCP 患者 发 生 不 良 妊 娠 结 局 的 预 测 价 值. 结 果:与 对 照 组 比 较,HDCP 组
血浆 f
i
c
o
l
i
n
３ 表达(
３２．
８５±８．
９６μg/L)高于对照组(
２０．
４７±６．
５８μg/L),
PTX３ 表 达(
２．
a
t
i
ngp
r
egnancy(HDCP)．Me
t
hods:At
o
t
a
lo
f１５３p
r
- 1、下载文档前请自行甄别文档内容的完整性，平台不提供额外的编辑、内容补充、找答案等附加服务。
- 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
- 3、如文档侵犯您的权益，请联系客服反馈,我们会尽快为您处理(人工客服工作时间：9:00-18:30)。
Inhibitors, Agonists, Screening LibrariesSafety Data Sheet Revision Date:Jan.-15-2018Print Date:Jan.-15-20181. PRODUCT AND COMPANY IDENTIFICATION1.1 Product identifierProduct name :HCGRP-(8-37)Catalog No. :HY-P1014CAS No. :119911-68-11.2 Relevant identified uses of the substance or mixture and uses advised againstIdentified uses :Laboratory chemicals, manufacture of substances.1.3 Details of the supplier of the safety data sheetCompany:MedChemExpress USATel:609-228-6898Fax:609-228-5909E-mail:sales@1.4 Emergency telephone numberEmergency Phone #:609-228-68982. HAZARDS IDENTIFICATION2.1 Classification of the substance or mixtureNot a hazardous substance or mixture.2.2 GHS Label elements, including precautionary statementsNot a hazardous substance or mixture.2.3 Other hazardsNone.3. COMPOSITION/INFORMATION ON INGREDIENTS3.1 SubstancesSynonyms:Human α–CGRP (8–37)Formula:C139H230N44O38Molecular Weight:3125.59CAS No. :119911-68-14. FIRST AID MEASURES4.1 Description of first aid measuresEye contactRemove any contact lenses, locate eye-wash station, and flush eyes immediately with large amounts of water. Separate eyelids with fingers to ensure adequate flushing. Promptly call a physician.Skin contactRinse skin thoroughly with large amounts of water. Remove contaminated clothing and shoes and call a physician.InhalationImmediately relocate self or casualty to fresh air. If breathing is difficult, give cardiopulmonary resuscitation (CPR). Avoid mouth-to-mouth resuscitation.IngestionWash out mouth with water; Do NOT induce vomiting; call a physician.4.2 Most important symptoms and effects, both acute and delayedThe most important known symptoms and effects are described in the labelling (see section 2.2).4.3 Indication of any immediate medical attention and special treatment neededTreat symptomatically.5. FIRE FIGHTING MEASURES5.1 Extinguishing mediaSuitable extinguishing mediaUse water spray, dry chemical, foam, and carbon dioxide fire extinguisher.5.2 Special hazards arising from the substance or mixtureDuring combustion, may emit irritant fumes.5.3 Advice for firefightersWear self-contained breathing apparatus and protective clothing.6. ACCIDENTAL RELEASE MEASURES6.1 Personal precautions, protective equipment and emergency proceduresUse full personal protective equipment. Avoid breathing vapors, mist, dust or gas. Ensure adequate ventilation. Evacuate personnel to safe areas.Refer to protective measures listed in sections 8.6.2 Environmental precautionsTry to prevent further leakage or spillage. Keep the product away from drains or water courses.6.3 Methods and materials for containment and cleaning upAbsorb solutions with finely-powdered liquid-binding material (diatomite, universal binders); Decontaminate surfaces and equipment by scrubbing with alcohol; Dispose of contaminated material according to Section 13.7. HANDLING AND STORAGE7.1 Precautions for safe handlingAvoid inhalation, contact with eyes and skin. Avoid dust and aerosol formation. Use only in areas with appropriate exhaust ventilation.7.2 Conditions for safe storage, including any incompatibilitiesKeep container tightly sealed in cool, well-ventilated area. Keep away from direct sunlight and sources of ignition.Recommended storage temperature:Powder-80°C 2 years-20°C 1 yearIn solvent-80°C 6 months-20°C 1 month7.3 Specific end use(s)No data available.8. EXPOSURE CONTROLS/PERSONAL PROTECTION8.1 Control parametersComponents with workplace control parametersThis product contains no substances with occupational exposure limit values.8.2 Exposure controlsEngineering controlsEnsure adequate ventilation. Provide accessible safety shower and eye wash station.Personal protective equipmentEye protection Safety goggles with side-shields.Hand protection Protective gloves.Skin and body protection Impervious clothing.Respiratory protection Suitable respirator.Environmental exposure controls Keep the product away from drains, water courses or the soil. Cleanspillages in a safe way as soon as possible.9. PHYSICAL AND CHEMICAL PROPERTIES9.1 Information on basic physical and chemical propertiesAppearance White to off-white (Solid)Odor No data availableOdor threshold No data availablepH No data availableMelting/freezing point No data availableBoiling point/range No data availableFlash point No data availableEvaporation rate No data availableFlammability (solid, gas)No data availableUpper/lower flammability or explosive limits No data availableVapor pressure No data availableVapor density No data availableRelative density No data availableWater Solubility No data availablePartition coefficient No data availableAuto-ignition temperature No data availableDecomposition temperature No data availableViscosity No data availableExplosive properties No data availableOxidizing properties No data available9.2 Other safety informationNo data available.10. STABILITY AND REACTIVITY10.1 ReactivityNo data available.10.2 Chemical stabilityStable under recommended storage conditions.10.3 Possibility of hazardous reactionsNo data available.10.4 Conditions to avoidNo data available.10.5 Incompatible materialsStrong acids/alkalis, strong oxidising/reducing agents.10.6 Hazardous decomposition productsUnder fire conditions, may decompose and emit toxic fumes.Other decomposition products - no data available.11.TOXICOLOGICAL INFORMATION11.1 Information on toxicological effectsAcute toxicityClassified based on available data. For more details, see section 2Skin corrosion/irritationClassified based on available data. For more details, see section 2Serious eye damage/irritationClassified based on available data. For more details, see section 2Respiratory or skin sensitizationClassified based on available data. For more details, see section 2Germ cell mutagenicityClassified based on available data. For more details, see section 2CarcinogenicityIARC: No component of this product present at a level equal to or greater than 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.ACGIH: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by ACGIH.NTP: No component of this product present at a level equal to or greater than 0.1% is identified as a anticipated or confirmed carcinogen by NTP.OSHA: No component of this product present at a level equal to or greater than 0.1% is identified as a potential or confirmed carcinogen by OSHA.Reproductive toxicityClassified based on available data. For more details, see section 2Specific target organ toxicity - single exposureClassified based on available data. For more details, see section 2Specific target organ toxicity - repeated exposureClassified based on available data. For more details, see section 2Aspiration hazardClassified based on available data. For more details, see section 212. ECOLOGICAL INFORMATION12.1 ToxicityNo data available.12.2 Persistence and degradabilityNo data available.12.3 Bioaccumlative potentialNo data available.12.4 Mobility in soilNo data available.12.5 Results of PBT and vPvB assessmentPBT/vPvB assessment unavailable as chemical safety assessment not required or not conducted.12.6 Other adverse effectsNo data available.13. DISPOSAL CONSIDERATIONS13.1 Waste treatment methodsProductDispose substance in accordance with prevailing country, federal, state and local regulations.Contaminated packagingConduct recycling or disposal in accordance with prevailing country, federal, state and local regulations.14. TRANSPORT INFORMATIONDOT (US)This substance is considered to be non-hazardous for transport.IMDGThis substance is considered to be non-hazardous for transport.IATAThis substance is considered to be non-hazardous for transport.15. REGULATORY INFORMATIONSARA 302 Components:No chemicals in this material are subject to the reporting requirements of SARA Title III, Section 302.SARA 313 Components:This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.SARA 311/312 Hazards:No SARA Hazards.Massachusetts Right To Know Components:No components are subject to the Massachusetts Right to Know Act.Pennsylvania Right To Know Components:No components are subject to the Pennsylvania Right to Know Act.New Jersey Right To Know Components:No components are subject to the New Jersey Right to Know Act.California Prop. 65 Components:This product does not contain any chemicals known to State of California to cause cancer, birth defects, or anyother reproductive harm.16. OTHER INFORMATIONCopyright 2017 MedChemExpress. The above information is correct to the best of our present knowledge but does not purport to be all inclusive and should be used only as a guide. The product is for research use only and for experienced personnel. It must only be handled by suitably qualified experienced scientists in appropriately equipped and authorized facilities. The burden of safe use of this material rests entirely with the user. MedChemExpress disclaims all liability for any damage resulting from handling or from contact with this product.Caution: Product has not been fully validated for medical applications. For research use only.Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA。